XBiotech

XBIT · Nasdaq · United States

Share price · XBIT

$1.73-0.54 (-23.79%) 3M

close as of 2026-11-18 · 24h delayed · vol 61K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when XBIT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Oct 2026+7.6%
  2. 26 Oct 2026-4.1%
  3. 19 Oct 2026-5.7%
  4. 12 Aug 2026+5.6%
  5. 6 Jul 2026+4.8%

    Nothing announced by XBIT that day or the session before.

  6. 3 Dec 2025+11.6%

    Nothing announced by XBIT that day or the session before.

  7. 1 Dec 2025+6.2%

    Nothing announced by XBIT that day or the session before.

Share of unusual movement by asset

For each asset, the share of XBIT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—17%
Sessions with no dated event—83%

No dated announcements about its assets since 2 Jul 2024.

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2
IL-1 alphaMonoclonal antibody
Rheumatoid Arthritis
514G3No recent activity
Phase 1/2
Staphylococcus aureus Protein A (SpA)Monoclonal antibody
Indication not yet linked

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
NatrunixPhase 2Rheumatoid Arthritis
Est. primary completion 2027-01-15 · NCT06590090 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (19)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$4.7M$105M$4.5M-$4.5M operating cash flowreport ↗
View 18 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$5.3M$110M$6.7M-$4.5M operating cash flowreport ↗
2026-Q1$0—$115M—-$9.0M operating cash flowreport ↗
2025-Q3—$5.1M$147M$6.0M-$4.3M operating cash flowreport ↗
2025-Q2—$5.3M$153M$1.8M-$6.0M operating cash flowreport ↗
2025-Q1—$12M$156M$11M-$6.7M operating cash flowreport ↗
2024-Q3—$7.1M$183M$5.0M-$5.8M operating cash flowreport ↗
2024-Q2—$13M$189M$13M-$11M operating cash flowreport ↗
2024-Q1—$9.8M$201M$10M-$7.2M operating cash flowreport ↗
2023-Q4——$200M+ $0 short-term inv.$4.6M-$3.4M operating cash flowreport ↗
2023-Q3$0$7.5M$202M+ $0 short-term inv.$7.4M-$1.5M operating cash flowreport ↗
2023-Q2$0$11M$143M+ $61M short-term inv.$8.7M-$9.0M operating cash flowreport ↗
2023-Q1$0$6.2M$152M+ $60M short-term inv.$3.8M-$4.8M operating cash flowreport ↗
2022-Q4——$157M+ $60M short-term inv.$3.2M$2.7M operating cash flowreport ↗
2022-Q3$1.7M$7.0M$161M+ $60M short-term inv.$13M-$6.0M operating cash flowreport ↗
2022-Q2$1.5M$10M$226M$12M-$6.4M operating cash flowreport ↗
2022-Q1$0.5M$6.8M$232M$5.4M-$5.1M operating cash flowreport ↗
2021-Q4——$237M+ $0 short-term inv.$6.5M-$1.8M operating cash flowreport ↗
2021-Q3$4.5M$5.6M$239M$3.3M-$3.4M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$47M$126M$11M-$40M operating cash flowreport ↗

For fiscal-year 2025, XBiotech did not disclose revenue. R&D spend was $47.39M, up 25.5% YoY from $37.76M. The company held $125.55M in cash and equivalents and reported a net loss of $45.54M, with quarterly net burn of $45.54M.

The company reported clinical progress across its True Human antibody pipeline. In oncology, Natrunix completed 120 weeks of dosing in a pancreatic cancer study, with reported reductions in hospitalization, serious adverse events and severe diarrhea, along with longer progression-free survival, and discussions with the FDA are ongoing. Its rheumatoid arthritis study was completed but deemed uninterpretable due to clinical-site irregularities, and that program was paused in December 2024. A Phase I stroke study of Hutrukin was completed, while a Phase II stroke study remains on hold. The infectious disease pipeline includes a clinical-stage MRSA therapeutic and preclinical programs for C. difficile, shingles and influenza, with investigational new drug applications for shingles and influenza targeted for the upcoming year.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$38M$173M$9.6M-$31M operating cash flowreport ↗
2023-FY$0$33M$200M+ $0 short-term inv.$6.1M-$19M operating cash flowreport ↗
2022-FY$4.0M$32M$157M+ $60M short-term inv.$8.2M-$15M operating cash flowreport ↗
2021-FY$18M$28M$237M+ $0 short-term inv.$4.3M$69M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($855K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-03SIMARD JOHN · director, 10% ownerOpen-market purchase70,000$2.05$143KForm 4
2026-10-26SIMARD JOHN · director, 10% ownerOpen-market purchase368,524$1.93$711KForm 4
2026-10-26Simard Jan-Paul · Co-Chief Executive OfficerAward / grant (derivative)2,000,000——Form 4
2025-10-01Troy Tevi David · directorAward / grant (derivative)56,000——Form 4
2025-10-01Kuendig Thomas Martin · directorAward / grant (derivative)79,115——Form 4
2025-10-01Soffer David Spencer · directorAward / grant (derivative)51,000——Form 4
2025-10-01Rademaker Craig Evan · directorAward / grant (derivative)92,104——Form 4
2025-03-17SIMARD JOHN · director, Chief Executive Officer, 10% ownerAward / grant (derivative)1,026,228——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 37 reporting institutions held 2.0M shares ($4.7M).

#InstitutionSharesValue
1BlackRock, Inc.293,104$689K
2GEODE CAPITAL MANAGEMENT, LLC231,020$543K
3VANGUARD CAPITAL MANAGEMENT LLC200,971$472K
4RBF Capital, LLC198,501$466K
5MORGAN STANLEY165,554$389K
6MILLENNIUM MANAGEMENT LLC105,540$248K
7BRIDGEWAY CAPITAL MANAGEMENT, LLC98,447$231K
8VANGUARD FIDUCIARY TRUST CO91,576$215K
9NORTHERN TRUST CORP76,087$179K
10STATE STREET CORP73,006$172K
11JANE STREET GROUP, LLC60,100$141K
12Empowered Funds, LLC59,547$140K
13Squarepoint Ops LLC41,214$97K
14Bank of New York Mellon Corp39,355$92K
15BANK OF AMERICA CORP /DE/36,689$86K